| Composition |
| Deslomar Syrup is containing 2.5 mg/5 mL desloratadine. |
| Side effect |
| in subjects 6 to 11 years of age, no individual adverse event was reported. may sometimes occurs pharyngitis, dry mouth, somnolence, and fatigue. |
| Pharmacodynamics properties |
| Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. |
| Pharmacokinetics |
| Food had no effect on the bioavailability (AUC and C max ) of DESLOMAR Syrup. Metabolism: Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Elimination: The mean elimination half-life of desloratadine was 27 hours. |
| Therapeutic indications |
Seasonal Allergic Rhinitis: DESLOMAR is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis.
Perennial Allergic Rhinitis: DESLOMAR is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis.
Chronic Idiopathic Urticaria: DESLOMAR is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. |
| Contraindication |
| DESLOMAR Tablets 5 mg are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients, or to loratadine. |
| Warnings and precautions |
| Carcinogenesis, Mutagenesis, Impairment of Fertility: The clinical significance of these findings during long-term use of desloratadine is not known. |
| Pregnancy and lactation |
Pregnancy Category C: There are, however, no adequate and well-controlled studies in pregnant women. Desloratadine should be used during pregnancy only if clearly needed.
Nursing Mothers: Desloratadine passes into breast milk; therefore a decision should be made whether to discontinue nursing or to discontinue desloratadine, taking into |
| Drug interactions |
| Clinical pharmacology studies showed that desloratadine was coadministered with erythromycin, ketoconazole, azithromycin, or fluoxetine. Although increased plasma concentrations (C max) of desloratadine and 3-hydroxydesloratadine were observed, there were no clinically relevant changes in the safety profile of desloratadine. |
| Dosage & administration |
Adults and children 12 years of age and over: DESLOMAR Syrup is 2 teaspoonfuls (5 mg in 10 mL) once daily.
Children 6 to 11 years of age: DESLOMAR Syrup is 1 teaspoonful (2.5 mg in 5 mL) once daily.
Children 12 months to 5 years of age: DESLOMAR Syrup is ½ teaspoonful (1.25 mg in 2.5 mL) once daily.
Children 6 to 11 months of age: DESLOMAR Syrup is 2 mL (1.0 mg) once daily. |
| Overdose |
| There was an increase in mean heart rate. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis. |
